GlassScriptPhysician profile
James B Hyatt
NPI 1891878427
$6,814.57
in general payments reported to CMS, 2019-2025
21 companies · $4,615 in 2025
The $4,615 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $17.11 · 2021: $129 · 2022: $618 · 2023: $530 · 2024: $772 · 2025: $4,615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $2,600 · Food and Beverage: $2,404 · Travel and Lodging: $883 · Education: $29.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $2,600.00 |
| Food and Beverage | $2,404.26 |
| Travel and Lodging | $882.51 |
| Education | $29.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $4,443.04 | 2024-2025 | Brixadi |
| Indivior INC. | $566.62 | 2022-2025 | Sublocade, Perseris |
| Alkermes, INC. | $357.39 | 2020-2025 | Aristada, Vivitrol, Lybalvi |
| Stryker Corporation | $249.94 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $225.66 | 2021-2023 | |
| Neurocrine Biosciences, INC. | $185.32 | 2022-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $138.85 | 2022-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Abbvie INC. | $135.66 | 2023 | |
| Vanda Pharmaceuticals INC. | $120.38 | 2022-2024 | Hetlioz, Fanapt |
| Vifor Pharma, INC. | $99.46 | 2019 | |
| Janssen Pharmaceuticals, INC | $75.21 | 2022-2025 | Invega |
| Sunovion Pharmaceuticals INC. | $60.95 | 2021 | |
| Glaxosmithkline, LLC. | $22.75 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $22.69 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.09 | 2025 | Trintellix |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $18.01 | 2024 | Auvelity |
| Idorsia Pharmaceuticals US INC | $16.29 | 2022 | |
| Lundbeck LLC | $15.60 | 2024 | Rexulti |
| Hikma Pharmaceuticals USA | $13.90 | 2024 | Kloxxado |
| Novartis Pharmaceuticals Corporation | $12.39 | 2019 | |
| Boston Scientific Corporation | $12.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hyatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.